STDs News

ID is a dynamic field that is constantly changing. The types of infections we’re talking about today are different than what we may have been talking about 5 years ago. So, it’s intellectually stimulating and challenging.

Three-quarters of people globally living with HIV are on ART, a roughly 30% increase during the last nine years, and fewer people acquired HIV in 2023 than at any point since the late 1980s, UNAIDS reported.

Post-exposure prophylaxis for HIV remained significantly underutilized, especially in acute care settings, according to study results published in Open Forum Infectious Diseases.

At a time when sexually transmitted infections have been described as an epidemic, primary care providers should counsel specific patients on doxycycline for post-exposure prophylaxis, according to an expert.

Only about half of gay or bisexual men received recommended sexually transmitted infection testing at their initial visit to a private, outpatient facility, researchers reported.

Rather than telling a patient they should get a vaccine, the CDC’s shared clinical decision-making recommendations advise patients to speak to providers about certain vaccines and decide on an individual basis if they should receive them. 

SAN ANTONIO — We caught up with Connie Steed, MSN, RN, CIC, FAPIC, at the annual meeting of the Association for Professionals in Infection Control and Epidemiology to find out how she got “Hooked on ID.”

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.

We checked in with CDC Director Mandy K. Cohen, MD, MPH, for an update on the agency’s efforts to modernize the nation’s disease surveillance and data systems and improve how the CDC communicates with the public and physicians.

The CDC has published guidance recommending that providers counsel certain patients on the harms and benefits of doxycycline for post-exposure prophylaxis — or doxy-PEP — for the prevention of sexually transmitted infections.